title: Other targetable sarcomas.
abstract: Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy. In addition, there are cancer cell survival pathways that may not be the target of chromosomal translocations or mutations that are still estimable targets for new systemic therapeutics, be it pathways involved in angiogenesis or apoptosis. In this review, we examine target selection for specific sarcoma subtypes, and demonstrate with a few examples new techniques being used to delineate novel therapeutic inroads for patients with sarcoma.
authors: Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors: Veridiana
authors: V
authors: Pires de Camargo
authors: Matt
authors: M
authors: van de Rijn
authors: Roberta
authors: R
authors: Maestro
authors: Enrique
authors: E
authors: de Alava
authors: Juan
authors: J
authors: Madoz-Gúrpide
authors: Silvana
authors: S
authors: Pilotti
authors: Margaret
authors: M
authors: von Mehren
authors: Florence
authors: F
authors: Pedeutour
authors: Robert G
authors: RG
authors: Maki
authors: Piotr
authors: P
authors: Rutkowski
authors: David M
authors: DM
authors: Thomas
mesh_terms: D002817:Chordoma / Q000188:drug therapy; D051358:Cyclin-Dependent Kinase 4 / Q000235:genetics; D055808:Drug Discovery; D006801:Humans; D008080:Liposarcoma / Q000188:drug therapy / Q000235:genetics; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D040901:Proteomics; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics; D012509:Sarcoma / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics
chemical_list: C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; C495900:CDK4 protein, human; D051358:Cyclin-Dependent Kinase 4